Skip to main content
. 2016 Sep 8;10(1):11–23. doi: 10.1007/s12154-016-0160-x

Table 3.

Anthelmintic activity data of synthesized compounds 3a–d, 4a–d and 5a–l

Comp Paralytic time (min)a Death time (min)a
Concentration (%) Concentration (%)
1 2 3 1 2 3
3a 12.17 ± 1.08 11.05 ± 1.28 10.30 ± 1.02 22.15 ± 0.75 20.25 ± 0.38 18.25 ± 0.64
3b 12.52 ± 1.03 11.40 ± 1.21 11.05 ± 0.78 23.20 ± 0.39 21.38 ± 1.12 19.35 ± 0.82
3c 13.35 ± 0.98 11.40 ± 1.05 11.15 ± 1.18 23.35 ± 1.13 21.24 ± 0.83 20.35 ± 0.73
3d 13.55 ± 0.68 12.40 ± 0.58 11.35 ± 0.88 23.20 ± 1.14 21.52 ± 1.12 21.39 ± 1.21
4a 27.54 ± 0.41 25.42 ± 0.72 23.41 ± 0.51 38.40 ± 0.53 35.27 ± 0.57 33.25 ± 1.05
4b 28.57 ± 0.41 25.52 ± 0.72 23.35 ± 0.51 39.45 ± 0.53 35.57 ± 0.57 33.39 ± 1.05
4c 29.47 ± 0.41 26.42 ± 0.72 24.31 ± 0.51 41.38 ± 0.53 37.53 ± 0.57 34.29 ± 1.05
4d 30.41 ± 0.41 27.47 ± 0.72 24.53 ± 0.51 42.35 ± 0.53 38.43 ± 0.57 35.32 ± 1.05
5a 19.58 ± 0.36 18.00 ± 1.07 15.54 ± 0.94 30.56 ± 0.45 28.55 ± 0.67 25.57 ± 0.92
5b 19.43 ± 0.59 17.54 ± 0.24 15.28 ± 0.30 30.10 ± 0.25 28.34 ± 0.47 25.32 ± 0.58
5c 19.58 ± 0.36 18.00 ± 1.07 15.54 ± 0.94 30.56 ± 0.45 28.55 ± 0.67 25.57 ± 0.92
5d 23.47 ± 0.41 20.57 ± 0.72 18.52 ± 0.51 34.50 ± 0.53 30.58 ± 0.57 28.49 ± 1.05
5e 23.58 ± 0.41 21.38 ± 0.72 19.52 ± 0.51 35.30 ± 0.53 31.43 ± 0.57 29.44 ± 1.05
5f 26.29 ± 0.41 23.46 ± 0.72 21.31 ± 0.51 36.33 ± 0.53 33.41 ± 0.57 31.30 ± 1.05
5 g 24.55 ± 0.41 22.56 ± 0.72 20.42 ± 0.51 35.42 ± 0.53 32.51 ± 0.57 30.10 ± 1.05
5 h 27.19 ± 0.41 24.36 ± 0.72 22.21 ± 0.51 37.43 ± 0.53 34.37 ± 0.57 32.15 ± 1.05
5i 13.58 ± 0.58 12.56 ± 0.63 11.48 ± 0.84 23.38 ± 0.67 22.00 ± 0.91 21.46 ± 0.49
5j 18.42 ± 0.38 17.11 ± 0.57 14.42 ± 0.67 29.42 ± 0.82 26.52 ± 1.04 24.12 ± 0.83
5 k 15.12 ± 0.25 14.11 ± 0.74 12.54 ± 0.62 25.14 ± 0.57 23.34 ± 0.43 22.15 ± 0.73
5 l 23.24 ± 0.41 20.35 ± 0.72 18.44 ± 0.51 34.32 ± 0.53 30.45 ± 0.57 28.38 ± 1.05
Std 10.37 ± 1.08 09.41 ± 0.64 08.17 ± 0.38 20.20 ± 0.94 18.15 ± 0.68 16.18 ± 0.83

Std albendazole

aMean ± SEM, n = 6